Scapho 150mg (Secukinumab )

 Secukinumab is a generic form of brand name scapho and scapho is a type of biological therapy which prevent the function of IL-17A proteins. This activity alters the immune activity and inflammation which cause the symptoms of psoriatic arthritis.

Scapho 150mg is used as prescription drug given by a doctor rheumatologist for adults with psoriatic arthritis and ankylosing spondylitis.

INDICATION

Scapho 150mg prescribed for the therapy of patients with following condition :

Plaque Psoriasis

Psoriatic arthritis

Ankylosing spondylitis

MECHANISM OF ACTION

Secukinumab consist of human IgG1 monoclonal antibody whichcarefullyconnects to the interleukin-17A (IL-17A) cytokine and prohibits its concomitant with the IL-17 receptor.

IL-17A is a naturally appearing cytokine included in normal inflammatory and immune responses. Secukinumab prevents the release of proinflammatory cytokines and chemokines.

ADME

Absorption: high plasma concentration for single dose is 6 days and weekly dosing for first month is 31-34 days Distribution: volume of distribution is 7.1 – 8.6 in IV administration Metabolism: Intracellular catabolism is the drug metabolized Elimination: half-life is 22-31 days

DOSAGE MANAGEMENT

Plaque Psoriasis :

Initial dose for the patients is given 300 mg SC at weeks 0, 1, 2, 3, and 4

initially at week 8, given 300 mg SC once monthly

The prescribed dose for plaque psoriasis is 150 mg may be acceptable for some patients

Psoriatic Arthritis :

The recommended dosage for Psoriatic arthritis for other patients, administer with or without a loading dosage by SC injection

Scapho the recommended dosewith loading dose administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter

Scaphothe recommended dose without loading dose administrated 150 mg SC q4wk.

Dosage of 300 mgshould be taken by patient ifcontinues to have active psoriatic arthritis,

May be given with or without methotrexate.

Ankylosing Spondylitis :

The recommended dose is given with or without a loading dosage by SC injection

Scapho the recommended dose with loading dose is administrated 150 mg SC at weeks 0, 1, 2, 3, and 4 and q4wk thereafter

Scapho the recommended dose without a loading dose is administrated150 mg SC q4wk

PRECAUTIONS

When using Scaphowill increased risk of infections; use with caution in patients with chronic infection or a history of recurrent infection

• Do not take vaccination of Secukinumab recipients with live virus vaccines because of probability of transmission of infection by vaccine

• When using scapho medication then Anaphylaxis and cases of urticaria resulted; if this appears, discontinue scapho immediately and start anaphylaxis treatment

• The treatment with Secukinumab should not be given to patients with active tuberculosis infection.

SIDE EFFECTS

Swelling under your skin

• Sores on your genital or anal areas

• Painful skin sores

• infections

• Nasopharyngitis

• Diarrhea

• URT infection

• Rhinitis

• Oral herpes

• Pharyngitis

• Urticaria

• Rhinorrhoea

DRUG INTERACTION

CYP450 substrates co administration with scapho injection may altered by increased levels of certain cytokines

Live vaccinations co administration with scapho should be avoided

CONTRAINDICATIONS

Patients having Serious hypersensitivity reactions to the active substance or to any of the excipients

PREGNANCY

Pregnancy category is B

Use the scapho 150mg with caution during pregnancy

LACTATION

Excretion into human milk is unknown. Use with caution while administrating scapho to a nursing woman

STORAGE 

Store the drug at 20°C – 80°C

Store in original carton and protect from light until the time of use

MISSED DOSE

If failed to take a dose, patients should consult with medical practitioner and follow the instructions given by them.